Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
Inventors
Weiner, David B. • Ferraro, Bernadette • Yan, Jian • Brown, Patricia A. • Bowling, Rodney A. • Kern, Douglas R. • Ramanathan, Mathura P. • Sardesai, Niranjan Y. • Muthumani, Karuppiah
Assignees
University of Pennsylvania • VGX Pharmaceuticals LLC • Inovio Pharmaceuticals Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12049479-B2
Publication Date
2024-07-30
Expiration Date
Abstract
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV.
Core Innovation
The description presents consensus FMDV capsid antigens VP1–VP4, individual VP1 antigens, and nucleic acids encoding these antigens for multiple FMDV subtypes, including A, Asia 1, C, O, SAT1, SAT2, and SAT3. The sequences are presented in plasmid or protein vaccines intended to elicit broad humoral and/or cellular immunity. Reported mouse examples demonstrate subtype-specific and cross-subtype antibody responses.
The description further presents vaccination with structural antigens as a basis for distinguishing vaccinated mammals from FMDV-infected mammals by detecting antibodies or proteins directed to FMDV nonstructural proteins. The background section is not included in the supplied content, so the specific problem being solved in that section is not explicitly described. The claims cover nucleic acids and protein compositions corresponding to specified sequences, immunogenic fragments, and variants.
Claims Coverage
The supplied claims recite two independent claims providing two inventive features.
Nucleic acid encoding specified FMDV proteins
An isolated nucleic acid comprising a sequence encoding one or more proteins corresponding to the listed SEQ ID NOs, with or without a leader sequence. The claim also covers complements, immunogenic fragments comprising at least 20 amino acids, and variants with at least 75% identity to the listed sequences.
Composition comprising specified FMDV proteins
A composition comprising one or more proteins corresponding to the listed SEQ ID NOs, with or without a leader sequence. The claim also covers complements, immunogenic fragments comprising at least 20 amino acids, and variants with at least 75% identity to the listed sequences.
The two inventive features encompass nucleic acids encoding specified FMDV proteins and compositions comprising those proteins, along with complements, immunogenic fragments, and sequence variants.
Stated Advantages
The vaccines are intended to elicit broad humoral and/or cellular immunity, providing subtype-specific and cross-subtype antibody responses.
Documented Applications
Plasmid or protein vaccines using the described FMDV antigens for vaccination against multiple FMDV subtypes.
Distinguishing vaccinated mammals from FMDV-infected mammals by detecting FMDV proteins or antibodies directed to proteins not included in the vaccine.
Interested in licensing this patent?